Hepatitis C virus inhibitors

Details Hepatitis C virus inhibitors Hepatitis C virus inhibitors

2008-01-29

2008-01-29

Tsang, Cscilia J. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C546S153000, C548S531000

Reexamination Certificate

active

11348721

ABSTRACT:
The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as “serine protease”) encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS3 protease.

REFERENCES:
patent: 6268207 (2001-07-01), Bailey
patent: 2005/0153877 (2005-07-01), Miao et al.
patent: 2006/0172950 (2006-08-01), Wang et al.
patent: 2006/0199773 (2006-09-01), Sausker et al.
patent: WO 98/17679 (1998-04-01), None
patent: WO 98/46597 (1998-10-01), None
patent: WO 99/07733 (1999-02-01), None
patent: WO 99/07734 (1999-02-01), None
patent: WO 00/09543 (2000-02-01), None
patent: WO 00/09558 (2000-02-01), None
patent: WO 2004/103996 (2000-02-01), None
patent: WO 00/59929 (2000-10-01), None
patent: WO 02/060926 (2002-08-01), None
patent: WO 03/064416 (2003-01-01), None
patent: WO 03/053349 (2003-07-01), None
patent: WO 03/064416 (2003-07-01), None
patent: WO 03/064455 (2003-08-01), None
patent: WO 03/064456 (2003-08-01), None
patent: WO 03/066103 (2003-08-01), None
patent: WO 03/099274 (2003-12-01), None
patent: WO 03/099316 (2003-12-01), None
patent: WO 2004/009121 (2004-01-01), None
patent: WO 2004/032827 (2004-04-01), None
patent: WO 2004/037855 (2004-05-01), None
patent: WO 2004/043339 (2004-05-01), None
patent: WO 2004/072243 (2004-08-01), None
patent: WO 2004/093798 (2004-11-01), None
patent: WO 2004/093915 (2004-11-01), None
patent: WO 2004/094452 (2004-11-01), None
patent: WO 2004/101602 (2004-11-01), None
patent: WO 2004/101605 (2004-11-01), None
patent: WO 2004/113365 (2004-12-01), None
patent: WO 2005/010029 (2005-02-01), None
patent: WO 2005/028501 (2005-03-01), None
patent: WO 2005/037214 (2005-04-01), None
patent: WO 2005/037860 (2005-04-01), None
patent: WO 2005/046712 (2005-05-01), None
patent: WO 2005/051410 (2005-06-01), None
patent: WO 2005/051980 (2005-06-01), None
patent: WO 2005/054430 (2005-06-01), None
patent: WO 2005/070955 (2005-08-01), None
patent: WO 2005/073216 (2005-08-01), None
patent: WO 2005/095403 (2005-10-01), None
patent: WO 2005/116054 (2005-12-01), None
patent: WO 2006/000085 (2006-01-01), None
patent: WO 2006/007700 (2006-01-01), None
patent: WO 2006/007708 (2006-01-01), None
patent: WO 2006/016930 (2006-02-01), None
patent: WO 2006/020276 (2006-02-01), None
patent: WO 2006/026352 (2006-03-01), None
patent: WO 2006/033878 (2006-03-01), None
patent: WO 2006/043145 (2006-04-01), None
patent: WO 2006/096652 (2006-09-01), None
patent: WO 2006/119061 (2006-11-01), None
patent: WO 2006/122188 (2006-11-01), None
U.S. Appl. No. 11/415,722, filed May 2, 2006, Wenying Li.
U.S. Appl. No. 11/481,536, filed Jul. 6, 2006, Hewawasam, et al.
Lauer, G.M. and Walker, B.D., “Hepatitis C Virus Infection”,N. Engl. J. Med., 2001, 345, 41-52.
Poupart, M.-A., Cameron, D.R., Chabot, C., Ghiro, E., Goudreau, N., Boulet, S., Poirier, M., and Tsantrizos, Y.S., “Solid-Phase Synthesis of Peptidomimetic Inhibitors for the Hepatitis C Virus NS3 Protease”,J. Org. Chem., 2001, 66, 4743-4751.
U.S. Appl. No. 11/591,253, filed Nov. 1, 2006, D'Andrea, et al.
Montse Llinas-Brunet, et al, “A Systematic Approach to the Optimization of Substrate-Based Inhibitors of the Hepatitis C Virus NS3 Protease: Discovery of Potent and Specific Tripeptide Inhibitors,” J. Med. Chem., 47, pp. 6584-6594, 2004.

Affiliated with

Also associated with

Rating

Hepatitis C virus inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hepatitis C virus inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis C virus inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3955702